Note 7 - Collaborative Agreements	3 Months Ended
Mar. 31, 2017
In Process Research and Development [Member]
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	NOTE 7 - COLLABORATIVE AGREEMENTS The Company and the University of Toronto, a stockholder of the Company (the “University”) entered into an agreement effective December 14, 2004 (the “Research Agreement”) for the performance of a research project titled “Evidence for existence of “Teneurin C-terminal Associated Peptide (“TCAP”) receptors in neurons” (the “Project”). The Research Agreement expired on March 31, 2013. The Company and the University entered into an agreement effective April 1, 2014 (the “New Research Agreement”) for the performance of a research project titled TCAP mediated stress attenuation in vertebrates: Establishing the role of organismal and intracellular energy and glucose regulation and metabolism" (the “New Project”). The New Project is to perform research related to work done by a professor at the University and stockholder of the Company (the “Professor”) in regard to TCAP mediated stress attenuation in vertebrates: Establishing the role of organismal and intracellular energy and glucose regulation and metabolism. In addition to the New Research Agreement, the Professor entered into an agreement with the University in order to commercialize certain technologies. The New Research Agreement expired on March 30, 2016. In February 2017, the New Research Agreement was extended to December 31, 2016 which allows for further development of the technologies and use of their applications. Upon expiration of the agreement, payments to the University and research support from the University will suspend until an agreement can be made. Prior to January 1, 2016, the University has been granted 25,000 stock options which are fully vested at the exercise price of $1.00 exercisable over a 10 year period which ends on April 1, 2022. As of March 31, 2017, the Professor has been granted 483,299 stock options, of which 275,000 are fully vested, at an exercise price of $1.00 exercisable over 10 or 13 year periods from the date of grant, which end either on March 30, 2021, December 1, 2022, April 15, 2026 or on March 1, 2027. The sponsorship research and development expenses pertaining to the Research Agreements were $23,002 and $3,000 for the periods ended March 31, 2017 and 2016, respectively.

NOTE

COLLABORATIVE AGREEMENTS

The Company and the University of Toronto, a stockholder of the Company (the “University”) entered into an agreement effective

December

14,

2004

(the “Research Agreement”) for the performance of a research project titled “Evidence for existence of “Teneurin C-terminal Associated Peptide (“TCAP”) receptors in neurons” (the “Project”). The Research Agreement expired on

March

31,

2013.

The Company and the University entered into an agreement effective

April

2014

(the “New Research Agreement”) for the performance of a research project titled TCAP mediated stress attenuation in vertebrates: Establishing the role of organismal and intracellular energy and glucose regulation and metabolism" (the “New Project”). The New Project is to perform research related to work done by a professor at the University and stockholder of the Company (the “Professor”) in regard to TCAP mediated stress attenuation in vertebrates: Establishing the role of organismal and intracellular energy and glucose regulation and metabolism. In addition to the New Research Agreement, the Professor entered into an agreement with the University in order to commercialize certain technologies. The New Research Agreement expired on

March

30,

2016.

February

2017,

the New Research Agreement was extended to

December

31,

2016

which allows for further development of the technologies and use of their applications. Upon expiration of the agreement, payments to the University and research support from the University will suspend until an agreement can be made.

Prior to

January

2016,

the University has been granted

25,000

stock options which are fully vested at the exercise price of

$1.00

exercisable over a

year period which ends on

April

2022.

As of

March

31,

2017,

the Professor has been granted

483,299

stock options, of which

275,000

are fully vested, at an exercise price of

$1.00

exercisable over

year periods from the date of grant, which end either on

March

30,

2021,

December

2022,

April

15,

2026

or on

March

2027.

The sponsorship research and development expenses pertaining to the Research Agreements were

$23,002

and

$3,000

for the periods ended

March

31,

2017

and

2016,

respectively.